《大行》里昂降康希诺生物(06185.HK)目标价至42.1元 维持“跑赢大市”评级

阿斯达克财经
02 May

里昂发表报告指,康希诺生物(06185.HK) 第一季营收按年增长20%,净亏损较去年同期减少90.2%,两者皆符合该行预测。据管理层表示,MCV4的销售势头持续,较去年同期增长约29%。管理层指指MCV4 取得双位数增长,并预期于2025年达到营运收支平衡。未来的主要催化因素是PCV13i疫苗于第二季获批,预计最迟于9月上市。

该行修订对康希诺生物预测,以反映其业绩及最新的生产线进展。目标价由43元小幅下调至42.1元,但维持“跑赢大市”评级。(ha/da)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)

AASTOCKS新闻

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10